Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
St.Shine Optical Co.,Ltd. (1565.TWO)
New Taipei City, TW
St.Shine Optical Co.,Ltd., headquartered in New Taipei City, Taiwan, is a prominent entity involved in the manufacturing, distribution, and sales of ophthalmic products, including contact lenses and optical lenses. The company's reach extends across diverse global markets, encompassing Asia, Europe, America, and Taiwan. Its extensive product portfolio features a variety of soft contact lenses, such as daily disposable, frequent replacement, and colored options, alongside advanced silicone hydrogel and traditional cast-molded types. These offerings are primarily marketed under the Ticon brand. The core purpose of their products is to rectify common vision impairments, specifically addressing refractive errors like myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. Established in 1986, the firm initially operated under the name First Optical Co., Ltd., adopting its current corporate identity, St.Shine Optical Co.,Ltd., in the same year.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.53% | -5.56% | -8.68% | -13.57% | -27.76% | -16.55% | -43.72% | -59.50% | -65.80% | -85.74% | +105.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-9.5% Q1'26: -19.0% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-38.6% Q1'26: -59.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.5% Q1'26: -13.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.1% Q1'26: +7.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+9.1% ★ Q1'26: +4.9% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.9% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.79× ★ Q1'26: 0.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.86B
est.
|
6.47B
est.
|
6.43B
est.
|
6.68B
est.
|
6.35B
est: 6.40B (-0.8%)
|
5.01B
est: 5.02B (-0.2%)
|
5.40B
est: 5.43B (-0.5%)
|
5.00B
est: 5.03B (-0.5%)
|
4.39B
est: 4.39B (+0.1%)
|
4.55B
est: 4.55B (+0.0%)
|
4.12B
est: 4.13B (-0.2%)
|
3.89B
3.89B – 3.89B
-5.8% YoY
|
| EBITDA |
1.59B
est.
|
1.76B
est.
|
1.74B
est.
|
1.81B
est.
|
1.99B
est: 1.74B (+14.6%)
|
1.28B
est: 1.36B (-5.6%)
|
1.48B
est: 1.47B (+0.7%)
|
1.62B
est: 1.37B (+18.9%)
|
1.01B
est: 1.19B (-15.1%)
|
1.23B
est: 1.12B (+10.1%)
|
540.40M
est: 1.02B (-46.8%)
|
957.60M
957.60M – 957.60M
-5.8% YoY
|
| EBIT |
1.21B
est.
|
1.33B
est.
|
1.33B
est.
|
1.38B
est.
|
1.63B
est: 1.32B (+23.6%)
|
954.77M
est: 1.03B (-7.7%)
|
1.16B
est: 1.12B (+4.0%)
|
1.29B
est: 1.04B (+24.4%)
|
689.15M
est: 904.90M (-23.8%)
|
951.80M
est: 883.96M (+7.7%)
|
540.40M
est: 801.95M (-32.6%)
|
755.51M
755.51M – 755.51M
-5.8% YoY
|
| Net Income |
1.47B
est.
|
1.81B
est.
|
1.63B
est.
|
1.68B
est.
|
1.29B
est: 1.33B (-3.5%)
|
745.11M
est: 736.47M (+1.2%)
|
947.76M
est: 968.11M (-2.1%)
|
1.02B
est: 1.03B (-1.0%)
|
545.95M
est: 558.36M (-2.2%)
|
747.30M
est: 730.80M (+2.3%)
|
455.03M
est: 579.50M (-21.5%)
|
490.47M
490.47M – 490.47M
-15.4% YoY
|
| SGA |
397.95M
est.
|
439.41M
est.
|
436.41M
est.
|
453.39M
est.
|
393.44M
est: 434.34M (-9.4%)
|
323.66M
est: 340.54M (-5.0%)
|
347.23M
est: 368.67M (-5.8%)
|
357.02M
est: 341.60M (+4.5%)
|
304.59M
est: 297.98M (+2.2%)
|
318.09M
est: 250.08M (+27.2%)
|
—
est: 226.88M (-100.0%)
|
213.74M
213.74M – 213.74M
-5.8% YoY
|
| EPS |
28.92
est.
|
35.67
est.
|
31.99
est.
|
33.11
est.
|
25.53
est: 26.23 (-2.7%)
|
14.78
est: 14.49 (+2.0%)
|
18.80
est: 19.04 (-1.3%)
|
20.21
est: 20.24 (-0.2%)
|
10.83
est: 10.98 (-1.4%)
|
14.82
est: 14.50 (+2.2%)
|
9.03
est: 11.50 (-21.5%)
|
9.73
9.73 – 9.73
-15.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 9.1K | 0.42% |
| 2 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 9.1K | 0.33% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 18.3K | 0.44% |
| 4 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 9.1K | 0.33% |
| 5 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 2.9K | 0.35% |
| 6 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 280.6K | 0.33% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 97.6K | 0.39% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 109.3K | 0.28% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 48.7K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eris Lin | Head of Finance & Accounting Department & Head of Corporate Governance | — | female |
| Ming-Hsien Chen | Chairman of the Board & Vice President of Greater China Businesses Department | — | male |
| Wan-Cheng Yang | Investment Manager | — | — |
| Ya Ping Lin | Accounting Supervisor | — | — |
| Yu Ran Chou | Chief Executive Officer & Director | — | male |
| Yu-Yu Chou | Manager of Administrative Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1565.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
